Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining...
Progression after high-dose melphalan with autologous stem cell transplantation (ASCT) in multiple myeloma (MM) may be due in part to immune dysfunction. Regulatory T (Treg) cells reconstitute rapidly after ASCT and inhibit immune responses against myeloma cells. The authors performed a...
Developing the ability to use tumor-directed therapies to trigger potentially therapeutic immune responses against cancer antigens remains a high priority for cancer immunotherapy. The authors hypothesized that histotripsy, a novel non-invasive, non-thermal ablation modality that uses ultrasound...
Ovarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT). However, the immunosuppressive ovarian tumor microenvironment and lack of tumor reactivity in TILs can limit the effectiveness of the...
Macrophages and dendritic cells lacking the transcription factor nuclear factor kappa B p50 are skewed toward a proinflammatory phenotype, with increased cytokine expression and enhanced T cell activation; additionally, murine melanoma, fibrosarcoma, colon carcinoma, and glioblastoma grow slower...
January 2020 JITC Reading List January 2020 The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC’s Commentary/editorials Section Editor, Christian Capitini, MD. “Trans-endocytosis of intact IL-15Ralpha–IL-15 complex from presenting...
Inside this Issue: Letter from the Editor JITC Editor Picks Other Recent JITC ARTICLES Letter from the Editor Dear JITC Readers, Welcome to the first JITC Digest of 2020! The past decade has seen cancer immunotherapy advance to an incredible degree, and the pace of innovation is not...
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as...
Throughout the 6 years of the Journal for ImmunoTherapy of Cancer ’s ( JITC ) existence, the field of cancer immunotherapy has changed dramatically. In 2013, when the journal was founded, no programmed death (PD)-1 inhibitors had yet been approved by the Food and Drug Administration (FDA); the...
The monoclonal antibody (mAb) trastuzumab is part of the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Antibody-dependent cell-mediated phagocytosis (ADCP) and cytotoxicity (ADCC) are major mechanisms of action of the mAb...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us